Keratoconjunctivitis Sicca
Showing NaN - NaN of 6
Dry Eye Syndromes, Keratoconjunctivitis Sicca Trial in United States (KPI-121 0.25% Ophthalmic Suspension, Vehicle of KPI-121
Completed
- Dry Eye Syndromes
- Keratoconjunctivitis Sicca
- KPI-121 0.25% Ophthalmic Suspension
- Vehicle of KPI-121 0.25% Ophthalmic Suspension
-
Phoenix, Arizona
- +59 more
Jan 19, 2021
Dry Eye Syndromes, Keratoconjunctivitis Sicca Trial in United States (KPI-121, Placebo)
Completed
- Dry Eye Syndromes
- Keratoconjunctivitis Sicca
- KPI-121
- Placebo
-
Artesia, California
- +10 more
Jan 4, 2021
Dry Eye Syndromes, Keratoconjunctivitis Sicca Trial in United States (KPI-121 0.25% Ophthalmic Suspension, Vehicle of KPI-121
Completed
- Dry Eye Syndromes
- Keratoconjunctivitis Sicca
- KPI-121 0.25% Ophthalmic Suspension
- Vehicle of KPI-121 0.25% Ophthalmic Suspension
-
Birmingham, Alabama
- +61 more
Dec 10, 2020
Dry Eye Syndrome, Keratoconjunctivitis Sicca Trial in Artesia, Newport Beach (Oculeve Intranasal Neurostimulator)
Completed
- Dry Eye Syndrome
- Keratoconjunctivitis Sicca
- Oculeve Intranasal Neurostimulator
-
Artesia, California
- +1 more
Sep 27, 2017
Keratoconjunctivitis Sicca Trial in United States (R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%, Placebo)
Completed
- Keratoconjunctivitis Sicca
- R348 Ophthalmic Solution, 0.2%
- +2 more
-
Artesia, California
- +19 more
Aug 9, 2016
